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Abstract
In this issue of Critical Care, Dutch investigators report that, in a
cohort of patients with sepsis/septic shock admitted to three
different intensive care units (ICUs), low central venous oxygen
saturation (ScvO2) was uncommon at the time of ICU admission,
and hospital mortality was <30%. Their findings, taken together
with those of recent reports from Australia and New Zealand
(ANZ), raise serious concerns about the utility of early goal
directed therapy (EGDT) outside the context of the original trial.
Despite inclusion of EGDT into the Surviving Sepsis Guidelines, in
response to growing uncertainty, ANZ and US investigators will
soon begin randomization of patients into two large multicentre
trials comparing EGDT to standard therapy. Until such studies are
completed, basing international treatment guidelines on a single
centre study performed in what may turn out to be a highly atypical
environment would seem premature.
Many physicians believe that global hypoxia secondary to
inadequate oxygen delivery (DO2) is responsible for organ
failure during severe sepsis. Others believe that sepsis is an
inflammatory condition in which abnormalities of DO2 are
uncommon. The relative importance of each of these
hypotheses, and indeed whether other unknown factors play
a role, is simply not known. The issue of DO2 and oxygen
consumption in sepsis is highlighted in the paper by van
Beest and colleagues [1] in this edition of Critical Care.
These authors have focused on central venous oxygen
saturation (ScvO2) as a marker of systemic oxygenation. They
have done this partly in response to the following fashionable,
but yet untested, concepts: first, ScvO2 is a reliable marker of
global tissue hypoxia; second, increasing ScvO2 by early goal
directed therapy (EGDT) [2] improves outcome; and third, we
should follow the Surviving Sepsis Campaign Guidelines [3]
by pursuing a SvcO2 >70% in septic patients. Their findings
suggest that the passive acceptance of the above conceptual
triad may be unwise. Only 6% of septic patients in their study
had a SvcO2 below physiological normality. The mean ScvO2
was 74%, compared to 48.9% in the EGDT study. Certainly,
the Dutch patients were different to those in the EGDT study
in several important respects: only half were admitted from
the emergency department, and many must have received
intravenous fluid prior to their intensive care unit (ICU)
admission. Despite comparable APACHE II scores, mortality
of septic patients in the Dutch study (26%) was much less
than in the EGDT standard care arm (46.5%), and less even
than in the intervention arm (30%) of that trial. Septic patients
presenting to a Dutch ICU would, therefore, be expected to
derive no benefit from EGDT-style attempts to increase their
(already normal) ScvO2.
These observations raise provocative questions about the
utility of applying the principles of EGDT outside the single
US urban hospital in which the trial was performed. Perhaps,
though, it is the Dutch data that are unique and unrepre-
sentative? This seems unlikely, as another study conducted in
Australia [4] reported essentially identical mortality (29%) to
that in the Netherlands, again below that reported by Rivers
and colleagues with EGDT, and almost half that seen in the
control group of that study. Perhaps the similarity of these
two studies is just coincidence. However, a further recent
study from Australia and New Zealand (ANZ) reported
hospital mortality from severe sepsis/septic shock was close
to 27% in 7,649 patients admitted to ICU from the emer-
gency department [5]. Even if these three independent and
remarkably consistent observations were dismissed as a
matter of chance, the recently completed ANZ Intensive Care
Society (ANZICS) Clinical Trials Group prospective study of
septic patients in more than 30 hospitals (soon to be
presented at the 2008 Brussels meeting) also found a 27%
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mortality rate. There is an elephant in the room: the baseline
mortality of severe sepsis/septic shock with standard care in
the Netherlands and ANZ is substantially less than in the
EGDT study. This raises serious concerns. Were the EGDT
study findings the result of re-alignment of limited quality care
back to a level considered acceptable elsewhere? Do they
apply to countries with ‘closed’ ICU systems [6] such as the
Netherlands and ANZ? Are the recommendations of the
Surviving Sepsis Campaign premature? In response to such
uncertainty, ANZICS has for now chosen not to endorse
these guidelines [7]. Indeed, once the virus of scepticism
takes hold one can see all sorts of uncertainties in the
biological construct and rationale underpinning EGDT. Is
there an oxygen debt in sepsis? Many would argue not
[8-10]. Is ScvO2 a robust marker of such global tissue
hypoxia? How would we know? What test would confirm or
refute whether such global hypoxia exists? Is high lactate a
marker of tissue hypoxia and ‘anaerobic metabolism’? The
answer to this last question is an easy, emphatic ‘absolutely
not’! [11-15]. Should we pursue EGDT in septic patients?
The answer is ‘not yet’. We need to assess the value of
EGDT in multicenter randomized controlled trials. The
ANIZCS Clinical Trials Group will soon begin an Australian
National Health and Medical Research Council-funded
randomised controlled trial, the Australasian Resuscitation In
Sepsis Evaluation (ARISE). This trial will randomize 1,500
patients and compare EGDT with standard care. US
investigators will soon begin ProCESS (Protocolized Care
Early Severe Sepsis), a similar NIH-funded multicentre trial to
address the same issue. Until the results of such trials are
available, the intensivist, emergency physician and hospital
administrator would do well to remain cautious about the
routine application of EGDT to their septic patients.
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